WARFASA Trial Summary The WARFASA trial aimed to evaluate the effectiveness of aspirin in preventing recurrent venous thromboembolism (VTE) in patients who had previously experienced an unprovoked VTE event. Approximately 20% of patients with unprovoked VTE experience a recurrence within two years after discontinuing oral anticoagulant therapy. While extended anticoagulation can prevent recurrences, it is […]
Tag: venous thromboembolism
ANT 005 TKA Trial: Abelacimab for VTE
2021 ANT-005 TKA TRIAL M Abelacimab for Prevention of Venous Thromboembolism (VTE) Phase 2,open-label, prospective randomized trial 400 Objective: To compare the efficacy & safety of abelacimab administered postoperatively with the efficacy & safety of enoxaparin in patients undergoing total knee arthroplasty. patients Inclusion criteria: Patients 18 to 80 years of age undergoing elective […]
AMPLIFY Trial: Apixaban for acute VTE
2013 AMPLIFY TRIAL Oral Apixaban for the Treatment of Acute Venous Thromboembolism double-blind, multicenter, randomized controlled trial IM Objective: To determine if apixaban is non-inferior to conventional therapy with LMWH in patients with pulmonary embolism or proximal deep venous thrombosis Inclusion criteria: Patients ≥18 years with symptomatic VTE, 5,395 either DVT proximal to popliteal vein […]
CATCH Trial Summary: Tinzaparin for VTE in Cancer
2015 CATCH TRIAL Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer phase 3, multinational, open-label, randomized controlled trial Objective: To assess the efficacy and safety of tinzaparin vs warfarin for treatment of acute, symptomatic venous thromboembolism (VTE) in patients with active cancer 900 Patients Inclusion criteria: Patients ≥ 18 […]
ADAM VTE Trial Summary: Apixaban in Cancer-associated VTE
2019 ADAM VTE TRIAL Apixaban and dalteparin in active malignancy-associated venous thromboembolism multicenter, randomized, open-label superiority trial 287 patients 0 Objective: To study side effects of and compare apixaban and dalteparin in reducing blood clots in patients with cancer-related VTE. Inclusion Criteria: Patients ≥ 18 years with confirmed active cancer within the prior 6 months […]
AXIOMATIC-TKR Trial Summary: Milvexian for the Prevention of VTE
2022 AXIOMATIC-TKR TRIAL Milvexian for the prevention of Venous thromboembolism Parallel-group, Open-label, randomized controlled trial Objective: To compare the efficacy & safety of milvexian and enoxaparin in patients undergoing elective knee arthroplasty 1242 patients INCLUSION CRITERIA: Patients undergoing unilateral total knee arthroplasty greater than 50 years of age without contraindicatior to enoxaparin or history of […]
ACTION Trial: Anticoagulation in COVID-19
2021 ACTION TRIAL Therapeutic vs. prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer Pragmatic, open-label (with blinded adjudication), multicentre, randomised Objective: to evaluate therapeutic anticoagulation compared with prophylactic anticoagulation among patients admitted with coronavirus disease 2019 (COVID-19) infection. 615 patients Inclusion Criteria: Patients (aged >18 years) hospitalised with COVID-19 and elevated […]